|
|
|
07238
|
|
|
P.I.:
|
Stephen Shibata, MD
|
|
|
Title:
|
PHI-60 NCI#8063: A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction
|
| | |
|
|
06249
|
|
|
P.I.:
|
Stephen Shibata, MD
|
|
|
Title:
|
A Random Assignment Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouacil (mDCF) versus Parent DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
|
| | |
|
|
06152
|
|
|
P.I.:
|
Stephen Shibata, MD
|
|
|
Title:
|
CALGB/SWOG C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
|
| | |
|
|
05130
|
|
|
P.I.:
|
Stephen Shibata, MD
|
|
|
Title:
|
Evaluation of Colon/Rectal Cancer Patterns and Outcomes of Care
|
|
|
04151
|
|
|
P.I.:
|
Stephen Shibata, MD
|
|
|
Title:
|
PHI-50 NCI#6432: A Phase I Pharmacokinetic Study of PS-341 in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group
|
| | |
|